HomeCompareBDSI vs KMB

BDSI vs KMB: Dividend Comparison 2026

BDSI yields 35.78% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDSI wins by $137.8K in total portfolio value
10 years
BDSI
BDSI
● Live price
35.78%
Share price
$5.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$183.7K
Annual income
$28,272.37
Full BDSI calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — BDSI vs KMB

📍 BDSI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDSIKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDSI + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDSI pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDSI
Annual income on $10K today (after 15% tax)
$3,041.14/yr
After 10yr DRIP, annual income (after tax)
$24,031.51/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, BDSI beats the other by $19,601.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDSI + KMB for your $10,000?

BDSI: 50%KMB: 50%
100% KMB50/50100% BDSI
Portfolio after 10yr
$114.8K
Annual income
$16,741.84/yr
Blended yield
14.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BDSI right now

BDSI
Analyst Ratings
9
Buy
2
Hold
Consensus: Buy
Altman Z
2.8
Piotroski
6/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDSI buys
0
KMB buys
0
No recent congressional trades found for BDSI or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDSIKMB
Forward yield35.78%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$183.7K$45.9K
Annual income after 10y$28,272.37$5,211.33
Total dividends collected$133.5K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: BDSI vs KMB ($10,000, DRIP)

YearBDSI PortfolioBDSI Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$14,278$3,577.82$11,314$613.68+$3.0KBDSI
2$20,051$4,774.15$12,865$759.19+$7.2KBDSI
3$27,721$6,266.08$14,709$943.96+$13.0KBDSI
4$37,758$8,096.12$16,919$1,180.17+$20.8KBDSI
5$50,707$10,305.96$19,588$1,484.33+$31.1KBDSI
6$67,191$12,934.95$22,838$1,879.06+$44.4KBDSI
7$87,913$16,018.70$26,832$2,395.60+$61.1KBDSI
8$113,655$19,587.81$31,788$3,077.63+$81.9KBDSI
9$145,277$23,666.62$38,000$3,986.82+$107.3KBDSI
10$183,719$28,272.37$45,872$5,211.33+$137.8KBDSI

BDSI vs KMB: Complete Analysis 2026

BDSIStock

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Full BDSI Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this BDSI vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDSI vs SCHDBDSI vs JEPIBDSI vs OBDSI vs KOBDSI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.